CL2021000648A1 - Piridazinonas y sus métodos de uso - Google Patents

Piridazinonas y sus métodos de uso

Info

Publication number
CL2021000648A1
CL2021000648A1 CL2021000648A CL2021000648A CL2021000648A1 CL 2021000648 A1 CL2021000648 A1 CL 2021000648A1 CL 2021000648 A CL2021000648 A CL 2021000648A CL 2021000648 A CL2021000648 A CL 2021000648A CL 2021000648 A1 CL2021000648 A1 CL 2021000648A1
Authority
CL
Chile
Prior art keywords
methods
pyridazinones
formula
compounds
disclosed
Prior art date
Application number
CL2021000648A
Other languages
English (en)
Inventor
Mark W Ledeboer
Matthew H Daniels
Maolin Yu
Jean-Christophe P Harmange
Original Assignee
Goldfinch Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goldfinch Bio Inc filed Critical Goldfinch Bio Inc
Publication of CL2021000648A1 publication Critical patent/CL2021000648A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compuestos de acuerdo con la Fórmula (I) y composiciones farmacéuticas relacionadas. También se divulgan métodos terapéuticos, por ejemplo, para tratar enfermedades renales, usando los compuestos de Fórmula (I).
CL2021000648A 2018-09-18 2021-03-16 Piridazinonas y sus métodos de uso CL2021000648A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862732728P 2018-09-18 2018-09-18
US201862780553P 2018-12-17 2018-12-17

Publications (1)

Publication Number Publication Date
CL2021000648A1 true CL2021000648A1 (es) 2021-08-06

Family

ID=69887813

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021000648A CL2021000648A1 (es) 2018-09-18 2021-03-16 Piridazinonas y sus métodos de uso

Country Status (28)

Country Link
US (3) US10654850B2 (es)
EP (2) EP3852533B8 (es)
JP (2) JP7474243B2 (es)
KR (1) KR20210069652A (es)
CN (1) CN112911935A (es)
AU (1) AU2019344928A1 (es)
BR (1) BR112021004926A2 (es)
CA (1) CA3113236A1 (es)
CL (1) CL2021000648A1 (es)
CO (1) CO2021004789A2 (es)
DK (1) DK3852533T3 (es)
EC (1) ECSP21026485A (es)
ES (1) ES2982498T3 (es)
FI (1) FI3852533T3 (es)
HR (1) HRP20240707T1 (es)
IL (1) IL281438B2 (es)
LT (1) LT3852533T (es)
MD (1) MD3852533T2 (es)
MX (1) MX2021003152A (es)
PE (1) PE20211774A1 (es)
PH (1) PH12021550443A1 (es)
PL (1) PL3852533T3 (es)
PT (1) PT3852533T (es)
RS (1) RS65558B1 (es)
SG (1) SG11202102053VA (es)
TW (1) TWI828758B (es)
UY (1) UY38377A (es)
WO (1) WO2020061162A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3852533B8 (en) * 2018-09-18 2024-07-17 Gfb (Abc), Llc Pyridazinones and methods of use thereof
WO2020206623A1 (en) * 2019-04-10 2020-10-15 Goldfinch Bio, Inc. Crystal forms
AR122450A1 (es) * 2020-05-08 2022-09-14 Lilly Co Eli Compuestos de (trifluorometil)pirimidin-2-amina
WO2022006278A1 (en) * 2020-07-01 2022-01-06 Angion Biomedica Corp. Reducing fibrosis and treating related diseases, disorders, and conditions
KR20230028522A (ko) * 2020-07-03 2023-02-28 우한 엘엘 사이언스 앤드 테크놀로지 디벨롭먼트 컴퍼니, 리미티드 헤테로고리 화합물 및 이의 용도
WO2022166817A1 (zh) * 2021-02-07 2022-08-11 武汉朗来科技发展有限公司 一种杂环化合物、其中间体、其制备方法及其应用
JP2024533411A (ja) * 2021-09-10 2024-09-12 メッドシャイン ディスカバリー インコーポレイテッド ハロゲン置換のピリダジノン系化合物及びその使用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA77526C2 (en) 2002-06-07 2006-12-15 Sanofi Aventis Substituted derivatives of 1-piperazineacylpiperidine, a method for the preparation thereof and their use in therapy
US20050165032A1 (en) 2004-01-23 2005-07-28 Norman Mark H. Vanilloid receptor ligands and their use in treatments
WO2005072308A2 (en) 2004-01-29 2005-08-11 Merck & Co., Inc. Cgrp receptor antagonists
DE102004044231A1 (de) 2004-09-14 2006-03-16 Henkel Kgaa Mittel zum Färben von keratinhaltigen Fasern
WO2006044504A1 (en) 2004-10-13 2006-04-27 Merck & Co., Inc. Cgrp receptor antagonists
PL2069312T3 (pl) 2006-07-25 2013-03-29 Cephalon Inc Pochodne pirydazynonu
CA2680587A1 (en) 2007-03-15 2008-09-25 Schering Corporation Piperazine-substituted pyridazinone derivatives useful as glucan synthase inhibitors
MX2010004705A (es) * 2007-10-31 2010-05-27 Nissan Chemical Ind Ltd Derivados de piridazinona y uso de los mismos como inhibidores del receptor p2x7.
WO2010017368A2 (en) * 2008-08-06 2010-02-11 Hydra Biosciences, Inc. Methods and compositions for treating anxiety
BR112013007499A2 (pt) * 2010-09-01 2016-07-12 Genentech Inc piridazinonas - métodos de criação e usos
KR20150023722A (ko) * 2012-06-12 2015-03-05 애브비 인코포레이티드 피리디논 및 피리다지논 유도체
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
JP6667093B2 (ja) 2014-08-11 2020-03-18 ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ， ＬＬＣ ピリド［２，３−ｄ］ピリミジン−２，４（１Ｈ，３Ｈ）−ジオン誘導体
EP3455219A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR THE DEGRADATION OF TARGET PROTEINS
WO2019055966A2 (en) 2017-09-18 2019-03-21 Goldfinch Bio, Inc. PYRIDAZINONES AND METHODS OF USE
US10703748B2 (en) 2017-10-31 2020-07-07 Samumed, Llc Diazanaphthalen-3-yl carboxamides and preparation and use thereof
EP3852533B8 (en) 2018-09-18 2024-07-17 Gfb (Abc), Llc Pyridazinones and methods of use thereof
US20220152031A1 (en) * 2019-03-20 2022-05-19 Goldfinch Bio, Inc. Pyridazinones and methods of use thereof
WO2020206623A1 (en) * 2019-04-10 2020-10-15 Goldfinch Bio, Inc. Crystal forms

Also Published As

Publication number Publication date
PL3852533T3 (pl) 2024-09-16
EP3852533A4 (en) 2022-06-15
US20200102301A1 (en) 2020-04-02
WO2020061162A1 (en) 2020-03-26
US10654850B2 (en) 2020-05-19
ECSP21026485A (es) 2021-07-30
SG11202102053VA (en) 2021-04-29
CN112911935A (zh) 2021-06-04
DK3852533T3 (da) 2024-05-27
RS65558B1 (sr) 2024-06-28
AU2019344928A1 (en) 2021-04-29
EP4414365A1 (en) 2024-08-14
BR112021004926A2 (pt) 2021-06-01
CA3113236A1 (en) 2020-03-26
FI3852533T3 (fi) 2024-05-24
MD3852533T2 (ro) 2024-08-31
HRP20240707T1 (hr) 2024-10-11
MX2021003152A (es) 2021-06-23
PE20211774A1 (es) 2021-09-08
IL281438B2 (en) 2023-12-01
US11046690B2 (en) 2021-06-29
US20220024917A1 (en) 2022-01-27
KR20210069652A (ko) 2021-06-11
TW202035402A (zh) 2020-10-01
TWI828758B (zh) 2024-01-11
JP2024099595A (ja) 2024-07-25
CO2021004789A2 (es) 2021-07-30
PH12021550443A1 (en) 2021-12-06
EP3852533A1 (en) 2021-07-28
EP3852533B1 (en) 2024-02-28
UY38377A (es) 2020-04-30
EP3852533B8 (en) 2024-07-17
ES2982498T3 (es) 2024-10-16
JP2022500359A (ja) 2022-01-04
PT3852533T (pt) 2024-05-31
IL281438A (en) 2021-04-29
US20200283437A1 (en) 2020-09-10
LT3852533T (lt) 2024-06-10
JP7474243B2 (ja) 2024-04-24
IL281438B1 (en) 2023-08-01

Similar Documents

Publication Publication Date Title
ECSP21026485A (es) Piridazinonas y sus métodos de uso
NI201900070A (es) Compuestos heterocíclicos como inmunomoduladores
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
WO2019055966A3 (en) PYRIDAZINONES AND METHODS OF USE
CO2018004124A2 (es) Compuestos heterocíclicos
EA201891494A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
EA202092896A1 (ru) Гетероциклические и гетероарильные соединения для лечения болезни гентингтона
EA201991399A1 (ru) Аминотриазолопиридиновые соединения и их применение в лечении рака
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
EA201790078A1 (ru) Ингибиторы mnk и связанные с ними способы
CO2018011408A2 (es) Compuestos de pirimidina como inhibidores de la quinasa jak
EA201992610A1 (ru) Экспансия -t-клеток, композиции и способы их применения
EA201691302A1 (ru) Новые гетероциклические соединения
CL2020002573A1 (es) Inhibidores atf6 y sus usos.
EA201692268A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA201792258A1 (ru) ТРИЦИКЛИЧЕСКИЕ СУЛЬФОНЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ RORγ
BR112018012177A2 (pt) ?moduladores de hidantação de canais kv 3?
CO2017011017A2 (es) Azabenzimidazoles y su uso como moduladores del receptor ampa
EA201990678A1 (ru) Гетероарилкарбоксамидные соединения в качестве ингибиторов ripk2
UY38233A (es) Agentes inhibidores para la tirosina cinasa de bruton
EA201891319A1 (ru) Соединения алкилдигидрохинолинсульфонамида
EA202190766A1 (ru) Иммуномодуляторы, их композиции и способы применения
EA201991045A1 (ru) Конденсированные азагетероциклические соединения и их применение в качестве модуляторов ampa-рецептора
EA201891680A1 (ru) Производные индана в качестве модуляторов mglur7
DOP2021000028A (es) Formulaciones de dendrímeros